Business Context and Reporting Period
This Form 8-K Current Report was filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on September 12, 2024, covering events occurring on September 12 and September 13, 2024. The Company is a Delaware corporation with its principal executive offices in Fremont, California, and its common stock trades on The Nasdaq Capital Market under the symbol "TIVC".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The report focuses on corporate governance and capital market activities. Key financial terms disclosed include:
- Equity Offering Capacity: The Company may sell up to $10,000,000 of common stock under a new Equity Distribution Agreement.
- Commission Fees: The sales agent, Maxim Group LLC, will receive a commission of 3.0% of aggregate gross proceeds.
- Reimbursement Cap: The Company agreed to reimburse the agent up to $40,000 for specified fees and expenses, plus $5,000 for each "bringdown."
- Executive Compensation: The new interim Chief Financial Officer will be paid $275 per hour as a non-employee consultant.
Material Changes
The filing discloses two material changes:
- Entry into Material Definitive Agreement: On September 13, 2024, the Company entered into an "at-the-market" (ATM) Equity Distribution Agreement with Maxim Group LLC. This agreement allows the Company to offer and sell shares of its common stock from time to time. The agreement terminates upon the sale of $10,000,000 in shares, 24 months from the date of the agreement, or upon mutual termination.
- Departure and Appointment of Officers: Kimberly Bambach resigned as interim Chief Financial Officer, effective October 1, 2024. She will remain with the Company in an advisory role. Lisa Wolf was appointed as the new interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective October 1, 2024.
Guidance, Outlook, and Risks
Outlook and Guidance: The filing contains no specific financial guidance or operational outlook. Management notes that the Company is not obligated to make any sales under the new ATM agreement, and no assurance can be given regarding the price, amount, or timing of any future sales.
Risks and Contingencies: The report includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to known and unknown risks. Specific risks associated with the ATM agreement include the uncertainty of share sales and market conditions.
Investor Verification Checklist
- Verify the correct registrant name is Tivic Health Systems, Inc. (TIVC), as the input metadata incorrectly referenced "Valion Bio, Inc."
- Confirm the effective date of the CFO transition is October 1, 2024.
- Review the attached Equity Distribution Agreement (Exhibit 1.1) for specific conditions precedent to share sales.
- Monitor future filings for actual sales activity under the $10,000,000 ATM facility.
- Check the Company's Form S-3 (File No. 333-269494) for the underlying shelf registration details.